PVAG - Phase I/II Dose Finding Trial in Elderly Patients (> 60 Years) With Advanced Stages Hodgkin's Lymphoma
Gemcitabine shows promising activity in patients with relapsed lymphoma either administered
as single agent or in combination with other cytotoxic agents. No trial to date evaluated
its role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly
regimen based on the standard ABVD regimen.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Dose-limiting toxicities and dose reductions
Andreas Engert
Principal Investigator
University of Cologne
Germany: Federal Institute for Drugs and Medical Devices
PVAG elderly
NCT00147875
March 2004
Name | Location |
---|